Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 1:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 2,224 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: ADD Clear all
Completed Phase 2 Interventional Results available

An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)

NCT03339297
View directory record Official record
Conditions
Graft-versus-host Disease, Acute-graft-versus-host Disease
Interventions
Defibrotide, Standard of Care
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Year and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
18
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Oct 28, 2026, 1:51 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT01364662
View directory record Official record
Conditions
Impulsive Aggression Comorbid With ADHD
Interventions
SPN-810, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
27
States / cities
Dothan, Alabama • Los Angeles, California • Santa Ana, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 28, 2026, 1:51 AM EDT
Completed Phase 3 Interventional Results available

Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia

NCT00856973
View directory record Official record
Conditions
Insomnia, Attention Deficit Hyperactivity Disorder
Interventions
eszopiclone, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
73
States / cities
Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2013 · Synced Oct 28, 2026, 1:51 AM EDT
Completed Phase 3 Interventional Results available

[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL

NCT01408303
View directory record Official record
Conditions
Hypertriglyceridemia, Cardiovascular Disease
Interventions
Olive oil, 4g, omega-3-carboxylic acids, 2g, omega-3-carboxylic acids, 4g
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
646 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
89
States / cities
Muscle Shoals, Alabama • Chandler, Arizona • Phoenix, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2014 · Synced Oct 28, 2026, 1:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sleep Extension and Behavior of Young Children

NCT03446716
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Sleep Extension
Behavioral
Lead sponsor
University of Massachusetts, Amherst
Other
Eligibility
6 Years to 9 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Amherst, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Oct 28, 2026, 1:51 AM EDT
Recruiting Phase 2 Interventional

Evaluating the Efficacy and Safety of Saline Irrigation as an Add-On Therapy for Retained Pleural Infections [LYTICS +]

NCT06713382
View directory record Official record
Conditions
Pleural Effusion Associated With Pulmonary Infection, Pleural Effusion Disorder, Pleural Effusions
Interventions
Pleural Saline Irrigation
Combination Product
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 28, 2026, 1:51 AM EDT
Recruiting Phase 2 Interventional

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

NCT05327686
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Renal Cell Carcinoma
Interventions
Avelumab, Axitinib, Biospecimen Collection, Bone Scan, Cabozantinib, Computed Tomography, Ipilimumab, Lenvatinib, Magnetic Resonance Imaging, Nivolumab, Pembrolizumab, Stereotactic Ablative Radiotherapy
Biological · Drug · Procedure + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
342
States / cities
Birmingham, Alabama • Kingman, Arizona • Phoenix, Arizona + 260 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 28, 2026, 1:51 AM EDT
Withdrawn Phase 2 Interventional

Tivozanib + Gemcitabine in Metastatic RCC

NCT01834183
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Tivozanib, Gemcitabine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
4
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 28, 2026, 1:51 AM EDT
Completed No phase listed Observational

Autism Spectrum Disorders (ASD) Driving Study

NCT01263756
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
16 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 8, 2011 · Synced Oct 28, 2026, 1:51 AM EDT
Terminated Not applicable Interventional Results available

Pilot Study of the Addition of Osmotic Dilators to Preparation Prior to Labor Induction Abortion

NCT00855842
View directory record Official record
Conditions
Abortion, Induced
Interventions
osmotic dilator insertion
Device
Lead sponsor
Boston University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 8, 2011 · Synced Oct 28, 2026, 1:51 AM EDT
Recruiting Phase 2 Interventional

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

NCT06770582
View directory record Official record
Conditions
Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v8
Interventions
Biospecimen Collection, Cisplatin, Computed Tomography, Fluorouracil, Gemcitabine, Magnetic Resonance Imaging, Mitomycin, Pembrolizumab, Questionnaire Administration, Radiation Therapy
Procedure · Drug · Biological + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
145
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Rogers, Arkansas + 103 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 28, 2026, 1:51 AM EDT
Completed Phase 3 Interventional Results available

A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms

NCT00541346
View directory record Official record
Conditions
Autism, Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate Transdermal System
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
6 Years to 11 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 28, 2026, 1:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Snacks, Smiles and Taste Preferences

NCT03631992
View directory record Official record
Conditions
Development, Child
Interventions
Low Sweet, Regular Sweet
Behavioral
Lead sponsor
Temple University
Other
Eligibility
3 Years to 6 Years
Enrollment
172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 28, 2026, 1:51 AM EDT
Completed Phase 2 Interventional Results available

Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®

NCT01477333
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
UT-15C SR, Tyvaso Inhalation Solution
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
Birmingham, Alabama • Rochester, Minnesota • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Oct 28, 2026, 1:51 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations

NCT04296604
View directory record Official record
Conditions
Traumatic Brain Injury, Major Depressive Disorder, Bipolar Disorder, Schizophrenia, Attention Deficit Hyperactivity Disorder, Borderline Personality Disorder, Substance Use Disorders
Interventions
Transcranial Direct Current Stimulation
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 28, 2026, 1:51 AM EDT
Terminated Phase 3 Interventional Results available

A Phase IIIb Study to Compare Entecavir Plus Tenofovir vs. Adefovir Added to Continuing Lamivudine Therapy in Adult Patients With Lamivudine-Resistant Hepatitis B Infection

NCT00605384
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Entecavir + Tenofovir, Adefovir + continuing Lamivudine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2010 · Synced Oct 28, 2026, 1:51 AM EDT
Recruiting Phase 2 Interventional

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

NCT06787612
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
Ubamatamab, Bevacizumab, Cemiplimab, Fianlimab, PLD, Sarilumab, REGN10597
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
21
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 28, 2026, 1:51 AM EDT
Recruiting Phase 1Phase 2 Interventional

Pathways 2 Success

NCT06831123
View directory record Official record
Conditions
Conduct Disorder, Oppositional Defiant Disorder
Interventions
L2B, L2B + App, skills for success
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
13 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 28, 2026, 1:51 AM EDT
Completed Phase 4 Interventional

GSK BHR Study (Sont - Second Study)

NCT01324362
View directory record Official record
Conditions
Asthma
Interventions
Placebo, FP 100mcg, FP 250mcg, FP 500mcg, FSC 100/50mcg, FSC 250/50mcg, FSC500/50mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
51
States / cities
Birmingham, Alabama • Jasper, Alabama • Glendale, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Oct 28, 2026, 1:51 AM EDT
Not listed Phase 2Phase 3 Interventional

BioFreedom US IDE Feasibility Trial

NCT02131142
View directory record Official record
Conditions
Ischemic Heart Disease, Stable Angina, Unstable Angina, Silent Ischemia
Interventions
BioFreedom drug coated coronary stent
Device
Lead sponsor
Biosensors Europe SA
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
13
States / cities
Washington D.C., District of Columbia • Miami, Florida • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Oct 28, 2026, 1:51 AM EDT
Completed No phase listed Observational

Pediatric Bipolar Disorder Study at UCLA

NCT00961935
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
7 Years to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Oct 28, 2026, 1:51 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Does Dapagliflozin Provide Additional Health Benefits To Dietary Counseling For Weight Loss?

NCT03180489
View directory record Official record
Conditions
Weight Loss
Interventions
Dapagliflozin Tablet, Placebo Tablet
Drug
Lead sponsor
Christopher Bell
Other
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Oct 28, 2026, 1:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Abuse Liability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation (ADAIR)

NCT04647903
View directory record Official record
Conditions
ADHD, Narcolepsy
Interventions
ADAIR 10 mg IR tablets, d-amphetamine sulfate, Placebo
Drug
Lead sponsor
Vallon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Oct 28, 2026, 1:51 AM EDT
Completed Not applicable Interventional

Efficacy of an Organizational Skills Intervention for Middle School Students With ADHD

NCT02150668
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
Homework, Organization, and Planning Skills (HOPS) Intervention, Homework Support Intervention (HSI)
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
11 Years to 15 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Oct 28, 2026, 1:51 AM EDT